Current clinical practice is guided by strong new evidence from randomized clinical trials (RCTs). These studies typically adhere to a strict prospective design with predetermined visits and scheduled examinations during follow-up. In the field of Nephrology, RCTs have primarily been developed to evaluate the effectiveness of new treatments in decreasing the risk of kidney failure, decline in estimated Glomerular Filtration Rate, and mortality or cardiovascular events. Nonetheless, advancements in informatics are evident in the enhancement and expansion of technologies and innovations in both current and future RCTs. In this context, we present several innovations and future directions for RCTs focused on patients with Chronic Kidney Disease.
Innovations in randomized clinical trials in Nephrology: from study design to patient’s activism
Malivindi R.;Veltri P.;Zaza G.;Provenzano M.
2025-01-01
Abstract
Current clinical practice is guided by strong new evidence from randomized clinical trials (RCTs). These studies typically adhere to a strict prospective design with predetermined visits and scheduled examinations during follow-up. In the field of Nephrology, RCTs have primarily been developed to evaluate the effectiveness of new treatments in decreasing the risk of kidney failure, decline in estimated Glomerular Filtration Rate, and mortality or cardiovascular events. Nonetheless, advancements in informatics are evident in the enhancement and expansion of technologies and innovations in both current and future RCTs. In this context, we present several innovations and future directions for RCTs focused on patients with Chronic Kidney Disease.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
